# Bevacizumab for Recurrent Malignant Glioma

> **NCT00271609** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 88 (actual)

## Conditions studied

- Recurrent High-Grade Gliomas
- Malignant Gliomas

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00271609
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2011-03
- **Final completion:** 2014-02
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271609, "Bevacizumab for Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00271609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*